Work

EGFR Mutant Subset Analysis From Archer 1009: a Randomized Double Blind Phase 3 Efficacy and Safety Study of Dacomitinib Versus Erlotinib for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

Year: 2015

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdv050.02

Authors: L. Paz-Ares, K. O'Byrne, T.S.K. Mok, M. Boyer, P.A. Jänne, Z. Goldberg, C. Mather, I. Taylor, H. Zhang, S.S. Ramalingam

Institutions: Hospital Universitario Virgen del Rocío, Princess Alexandra Hospital, Chinese University of Hong Kong, Prince of Wales Hospital, Chris O’Brien Lifehouse, Dana-Farber Cancer Institute, Pfizer (United States), Winship Cancer Institute

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2073494782

FWCI:

Cites:

Cited by:

Related to: 10